Regulatory approval received for acquisition of Kemwell Indian operations
Further to the announcement on 18th April 2016 that Recipharm would acquire the pharma division of Kemwell’s Indian operation, the Indian Foreign Investment Promotion Board has now granted approval for this transaction to take place.Closing is expected to occur at the beginning of 2017 and comprises the acquisition of Kemwell’s pharmaceutical manufacturing and development operations located in Bengaluru known as Recipharm Pharmaservices Private Ltd. For more information please visit www.recipharm.com or contact: Thomas Eldered, CEO, thomas.eldered@recipharm.com, telephone: +46 8 602